Video unavailable
This video can't be played right now.
Early treatment versus ‘watch and wait’ for CLL
Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL) that were presented at the 2014 American Society of Hematology (ASH) Annual Meeting. The understanding of the biology of CLL is changing how we manage CLL. Prognostic markers help to identify specific patient subgroups and provide insight on how disease will progress in these groups. New studies in drugs, such as ibrutinib, affect cell proliferation. Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network
Suggested videos
CLL: What is 'watch & wait' and what can a patient do during this phase?
Mayo Clinic · 4:19
The era of personalised medicine in cancer treatment
Patient Power Europe · 1:01
Potential of early intervention in CLL: should the watch-and-wait strategy remain standard?
VJHemOnc – Video Journal of Hematology & HemOnc · 1:34
Post-treatment support: why is it important and where to get it
Patient Power Europe · 2:28
When Does CLL Need Treatment? Watch and Wait, Treatment Timing, and the Possibility of a Cure
HealthTree Foundation for Lymphoma and HealthTree Foundation for Leukemia · 6:11
How long does radiation therapy last?
Patient Power Europe · 1:06
What is Watch and Wait in CLL?
Patient Empowerment Network · 2:53
Palliative care for advanced cancer patients: why we do it and when should we do it?
Patient Power Europe · 2:06
Provider Connections: Dr. Neil Kay on Newly Diagnosed Chronic Lymphocytic Leukemia, Watch and Wait
Mayo Clinic · 12:34
Cancer patients: Become the CEO of you
Patient Power Europe · 1:19
What Happens During CLL “Watch and Wait”?
Patient Empowerment Network · 2:18
Helping patients help themselves
Patient Power Europe · 2:02